MX2022005670A - Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn. - Google Patents

Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn.

Info

Publication number
MX2022005670A
MX2022005670A MX2022005670A MX2022005670A MX2022005670A MX 2022005670 A MX2022005670 A MX 2022005670A MX 2022005670 A MX2022005670 A MX 2022005670A MX 2022005670 A MX2022005670 A MX 2022005670A MX 2022005670 A MX2022005670 A MX 2022005670A
Authority
MX
Mexico
Prior art keywords
methods
compositions
rna molecules
molecules
reconstitution
Prior art date
Application number
MX2022005670A
Other languages
English (en)
Inventor
Lukas Christoph Bachmann
Samuel Lawrence Pfaff
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2020/025430 external-priority patent/WO2020205604A1/en
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Publication of MX2022005670A publication Critical patent/MX2022005670A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
    • C12N2840/445—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor for trans-splicing, e.g. polypyrimidine tract, branch point splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se proporcionan en la presente composiciones y sistemas para reconstitución de moléculas de ARN, que incluyen métodos para utilizar estas moléculas. Por ejemplo, tales moléculas se pueden utilizar para suministrar una secuencia de codificación de proteína sobre dos o más vectores virales (tales como AAVs), que da por resultado la reconstitución de la proteína de longitud completa en una célula. Tales métodos se pueden utilizar para suministrar una proteína terapéutica, por ejemplo para tratar una enfermedad genética o cáncer.
MX2022005670A 2019-11-11 2020-09-30 Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn. MX2022005670A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933714P 2019-11-11 2019-11-11
PCT/US2020/025430 WO2020205604A1 (en) 2019-03-29 2020-03-27 High-efficiency reconstitution of rna molecules
PCT/US2020/053643 WO2021096605A1 (en) 2019-11-11 2020-09-30 Compositions and methods for high-efficiency recombination of rna molecules

Publications (1)

Publication Number Publication Date
MX2022005670A true MX2022005670A (es) 2022-07-19

Family

ID=75911442

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005670A MX2022005670A (es) 2019-11-11 2020-09-30 Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn.

Country Status (11)

Country Link
US (1) US20220265855A1 (es)
EP (1) EP4058571A1 (es)
JP (1) JP2023500957A (es)
KR (1) KR20220113940A (es)
CN (1) CN114945666A (es)
AU (1) AU2020384996A1 (es)
BR (1) BR112022009006A2 (es)
CA (1) CA3157799A1 (es)
IL (1) IL292904A (es)
MX (1) MX2022005670A (es)
WO (1) WO2021096605A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021225035A1 (en) 2020-02-21 2022-10-13 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110743A (en) 1995-02-10 2000-08-29 The Regents Of The University Of California Development and use of human pancreatic cell lines
US20060134658A1 (en) * 2004-08-09 2006-06-22 Garcia-Blanco Mariano A Use of RNA trans-splicing for generation of interfering RNA molecules

Also Published As

Publication number Publication date
IL292904A (en) 2022-07-01
WO2021096605A1 (en) 2021-05-20
CN114945666A (zh) 2022-08-26
KR20220113940A (ko) 2022-08-17
BR112022009006A2 (pt) 2022-10-11
CA3157799A1 (en) 2021-05-20
AU2020384996A1 (en) 2022-06-23
JP2023500957A (ja) 2023-01-11
US20220265855A1 (en) 2022-08-25
EP4058571A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
ZA202002094B (en) Trispecific proteins and methods of use
MX2020004578A (es) Composiciones de casz y metodos de uso.
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2022004786A (es) Variante de aav2 con aflibercept para usarse en el tratamiento de una condicion o enfermedad ocular.
AU2016262093A8 (en) Enhancing endonuclease based gene editing in primary cells
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
EP4339287A3 (en) Modified cells and methods of therapy
EP4321623A3 (en) Methods and compositions for genome editing in non-dividing cells
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
MX2018004263A (es) Edición genómica multiplexada.
PH12020550039A1 (en) Sialyltransferases and their use in producing sialylated oligosaccharides
MA37681A2 (fr) Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie
MX2022004042A (es) Proteinas de union multiespecificas para tratamiento contra el cancer.
BRPI0714495B8 (pt) lentivírus deficiente para replicação recombinante pseudotipado
MX2020010994A (es) Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial.
MX2021014525A (es) Adenovirus modificados.
MX2021000638A (es) Métodos y composiciones de construcciones y vectores de acidemia metilmalónica.
CR20220317A (es) Anticuerpos anti-cd73 y usos de estos
MX2021008874A (es) Adn de extremo cerrado (ceadn) y uso en metodos de reduccion de la respuesta inmunitaria relacionada con tratamiento genico o de acido nucleico.
MX2022006188A (es) Variantes del vector viral adenoasociado.
WO2014026110A3 (en) Compounds for improved viral transduction
IN2015DN03206A (es)
WO2021133959A3 (en) Compositions and methods for gamma delta tcr reprogramming using fusion proteins
MX2021012158A (es) Métodos para la integración de una secuencia de adn donante en el genoma de bacillus usando constructos de adn recombinante lineal y composiciones de los mismos.
MX2019015143A (es) Rna guias modificados, complejos crispr-ribonucleoproteina y metodos de uso.